Abstract 9000 Outcomes of anti-PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score
Abstract LBA2 Phase III assessment of topotecan & cyclophosphamide and high-dose ifosfamide in rEECur, an international randomised controlled trial of chemotherapy for the treatment of